Summit Therapeutics to Present at the Needham Heal
Post# of 301275
OXFORD, United Kingdom, March 30, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT ) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr. Glyn Edwards, Chief Executive Officer, will present at the Needham Healthcare Conference, 5 April 2017 at 11:20am EDT in New York City.
A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com . A replay of the webcast will be available soon after the live presentation.
About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Therapeutics | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: +44 (0)1235 443 951 | |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP | ||
| (Nominated Adviser) | ||
| Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7213 0880 | |
| N+1 Singer | ||
| (Broker) | ||
| Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 | |
| MacDougall Biomedical Communications | ||
| (US media contact) | Tel: +1 781 235 3060 | |
| Karen Sharma | ksharma@macbiocom.com | |
| Consilium Strategic Communications | ||
| (Financial public relations, UK) | Tel: +44 (0)20 3709 5700 | |
| Mary-Jane Elliott / Sue Stuart / | summit@consilium-comms.com | |
| Jessica Hodgson / Lindsey Neville | ||
-END-
(0)
(0)